General
Preferred name
EMEDASTINE
Synonyms
EMEDASTINE DIFUMARATE ()
LY188695 ()
Emadine ()
Rapimine, Emedastine fumarate ()
LY-188695 ()
Emedastine fumarate ()
KB-2413 ()
AL-3432A ()
Rapimine ()
Emedastine (fumarate) ()
Emedastine-13C-d3 (fumarate) ()
P&D ID
PD009817
CAS
87233-61-2
87233-62-3
Tags
available
drug
Approved by
FDA
First approval
1997
Drug Status
approved
Drug indication
Antihistaminic, H1-Receptor
Anti-Allergic
Asthma Prophylactic
Allergic conjunctivitis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Following oral administration, approximately 44% of the total dose can be recovered in the urine over the 24-hour period, with only 3.6% of the dose excreted as unchanged form. Two primary metabolites, 5- and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms.
MOA Emedastine is a relatively selective, histamine H1 antagonist. In vitro examinations of emedastine's affinity for histamine receptors demonstrate relative selectivity for the H1 histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastine appears exert negligible effects on adrenergic, dopaminergic and serotonin receptors.
METABOLISM Two primary metabolites, 5-hydroxyemedastine and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. Minor metabolites include the 5'-oxoanalogs of 5-hydroxyemedastine and 6-hydroxy-emedastine and the N-oxide.
HALF-LIFE The elimination half-life in the plasma is 3-4 hours following oral administration.
DESCRIPTION Emedastine is an antihistamine. (GtoPdb)
DESCRIPTION Emedastine is a potent, high affinity and selective antagonist of histamine H1-receptor with Ki of 1.3 for H1-receptors while significantly weaker at H2- (K1 = 49,067 nM) and H3-receptors (Ki = 12,430 nM). (BOC Sciences Bioactive Compounds)
Compound Sets
20
BOC Sciences Bioactive Compounds
emedastine-cas-87233-61-2-item-99597
Cayman Chemical Bioactives
23946
33378
ChEMBL Approved Drugs
CHEMBL2103739
CHEMBL594
ChEMBL Drugs
CHEMBL2103739
CHEMBL594
Drug Repurposing Hub
DrugBank
DB01084
DrugBank Approved Drugs
DB01084
DrugCentral
999
DrugCentral Approved Drugs
999
DrugMAP
DM36LAJ
DrugMAP Approved Drugs
DM36LAJ
DrugMatrix
Guide to Pharmacology
7174
MedChem Express Bioactive Compound Library
HY-108411
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
emedastine-difumarate
emedastine
TargetMol Bioactive Compound Library
T3979
The Spectrum Collection
External IDs
49
Properties
(calculated by RDKit )
Molecular Weight
302.21
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
2.21
TPSA
33.53
Fraction CSP3
0.59
Chiral centers
0.0
Largest ring
7.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Target
H1 receptor
HRH1
Histamine Receptor
Indication
conjunctivitis
MOA
Histamine Receptor antagonist
Therapeutic Class
Antiallergic Agents
Source data